By quantifying T-DM1+P–induced transcriptional changes, we observed minimal transcriptomic responses in HET tumors despite the presence of HER2-positive cancer cells, implying key biological differences between HER2-HET and non-HET tumors. The gene discussed is ERBB2; the disease is cancer.